Unraveling The Key Questions in EGFR-Driven NSCLC Treatment - Episode 4
Panelists discuss how managing adverse events (AEs) with osimertinib requires proactive monitoring and intervention, with monotherapy generally being well-tolerated aside from common AEs like rash and diarrhea.
Video content above is prompted by the following: